Cryoport Q1 revenue rises 16% YoY to $47.8M, boosts full-year guidance to $192-$196M

Cryoport reported a 16% year-over-year revenue increase to $47.8 million in Q1 2026, driven by strong growth in commercial cell and gene therapy (CGT) revenue, which rose 26% to $9.1 million. Life Sciences Services and Products segments also grew, supporting 766 global clinical trials and 21 approved CGTs. The company raised its full-year revenue guidance to $192-$196 million, citing ongoing expansion and new supply chain centers opening in Paris and California later this year. This positions Cryoport for continued growth in the life sciences temperature-controlled supply chain market.